Fineman, Mark S.
McAlindon, Timothy E.
Lattermann, Christian
Swearingen, Christopher J.
Kennedy, Sarah
Lopez, Victor A.
Simsek, Ismail
Tambiah, Jeyanesh R. S.
Yazici, Yusuf
Clinical trials referenced in this document:
Documents that mention this clinical trial
Safety, Tolerability, and Pharmacokinetics of Same-Knee Intra-Articular Injection of Corticosteroid and Lorecivivint Within 7 Days: An Open-Label, Randomized, Parallel-Arm Study
https://doi.org/10.1007/s40744-023-00604-7
Funding for this research was provided by:
Biosplice Therapeutics
Article History
Received: 23 June 2023
Accepted: 22 September 2023
First Online: 30 October 2023
Declarations
:
: Mark Fineman, PhD, Christopher J. Swearingen, PhD, Sarah Kennedy, PhD, Victor A. Lopez, MS, Ismail Simsek, MD, Jeyanesh R.S. Tambiah, MD, and Yusuf Yazici, MD are current or past employees and shareholders of Biosplice Therapeutics. Timothy McAlindon, MD, MPH, is a consultant and investigator for Biosplice Therapeutics, a consultant to Kolon TissueGene, Organogenesis, Remedium-Bio, Medipost, ChemoCentryx, and Xalud, with business interest in Ambulomics, Inc. Christian Lattermann, MD is a consultant for Biopslice Therapeutics and a consultant to Organogenesis, Aesculap and Vericel, Scientifc Board Member of On-Foundation.
: The research within this clinical trial was conducted in accordance with the Declaration of Helsinki, the International Council for Harmonisation Good Clinical Practice Guidelines, and all applicable regulations. The trial was conducted under institutional review board approval by Advarra (Columbia, MD) (approval date 7 October 2020, approval reference MOD00817729). All participants provided written informed consent prior to engaging in any study-related procedures.